The Leafcann Group: an emerging leader in Australian medical cannabis research

The Leafcann Group. an emerging leader in Australian medical cannabis research

In the world of medical cannabis research, Leafcann showcase their impressive record and intention to extend their services into the European market.

LeafCann is an Australian Office of Drug Control licenced, vertically integrated biotech company specialising in the production of high quality, pharmaceutical grade cannabis ingredients and medicines. Through its subsidiary, Alchemy Bioservices, the world’s first Registered Training Organisation (RTO) dedicated to the training, professionalisation and management of the emerging Medicinal Cannabis workforce – could this take medical cannabis research to the next level?

The LeafCann Group was borne out of a desire to provide patients with a safe, natural alternative for difficult to treat conditions, where there is currently no existing, safe and effective pharmaceutical treatment. CEO and co-founder, Elisabetta Faenza says, “After

... read more at: https://www.healtheuropa.eu/leafcann-australian-medical-cannabis-research/92288/

Leave a Reply